Mani Foroohar
Stock Analyst at Leerink Partners
(1.98)
# 3,014
Out of 4,829 analysts
173
Total ratings
50%
Success rate
6.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $2.63 | +584.41% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.64 | +29.31% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $3.32 | +713.25% | 9 | Jan 13, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $46 → $44 | $7.00 | +528.57% | 10 | Nov 19, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $17.70 | +306.78% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $2.10 | +709.52% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $45.57 | +7.53% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $35.68 | +28.92% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $6.60 | +233.33% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $33.53 | +84.91% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $13.14 | -1.07% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $24.17 | +19.98% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $36.37 | +532.39% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $3.62 | +10.50% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.97 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $2.97 | +943.77% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.41 | +1,602.75% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $13.97 | +186.33% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $25.70 | +261.87% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $8.55 | +882.46% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.54 | +354.55% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $180 → $160 | $3.29 | +4,763.22% | 10 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $18.24 | +322.15% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $270.19 | -47.07% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.60 | +7.14% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $37.59 | +102.18% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $0.82 | +4,055.97% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.71 | +638.01% | 6 | Jul 23, 2021 |
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $2.63
Upside: +584.41%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.64
Upside: +29.31%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $3.32
Upside: +713.25%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $44
Current: $7.00
Upside: +528.57%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $17.70
Upside: +306.78%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $2.10
Upside: +709.52%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $45.57
Upside: +7.53%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $35.68
Upside: +28.92%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.60
Upside: +233.33%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $33.53
Upside: +84.91%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $13.14
Upside: -1.07%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $24.17
Upside: +19.98%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $36.37
Upside: +532.39%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $3.62
Upside: +10.50%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $7.97
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $2.97
Upside: +943.77%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.41
Upside: +1,602.75%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $13.97
Upside: +186.33%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $25.70
Upside: +261.87%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $8.55
Upside: +882.46%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.54
Upside: +354.55%
Jan 23, 2023
Maintains: Market Perform
Price Target: $180 → $160
Current: $3.29
Upside: +4,763.22%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $18.24
Upside: +322.15%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $270.19
Upside: -47.07%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.60
Upside: +7.14%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $37.59
Upside: +102.18%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $0.82
Upside: +4,055.97%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.71
Upside: +638.01%